* Affymetrix Inc., of Santa Clara, Calif., launched its GeneChip cytochrome P450 assay for research applications. The assay, developed in collaboration with Hewlett-Packard Inc., of Palo Alto, Calif., is designed to work faster and be more informative than currently used genotyping methods. It is the first commercially available DNA probe array-based assay for the simultaneous detection of 18 known genetic variants of two human cytochrome genes, 2D6 and 2C19.

* ArQule Inc., of Medford, Mass., and ViroPharma Inc., of Malvern, Pa., said they are collaborating for discovery and development of therapeutics for RNA viruses. The collaboration provides ViroPharma with access to ArQule's Mapping Array program, which comprises libraries of compounds used against biological targets in new product discovery. If leads are identified, the companies will use ArQule's Directed Array program to optimize them.

* Cell Genesys Inc., of Foster City, Calif., said its collaborators at The Salk Institute, of San Diego, have achieved successful long-term gene delivery to liver and muscle tissues, using second-generation lentiviral vectors. Scientists used a "marker" gene to evaluate the effectiveness of gene delivery to liver and muscle tissue of rodents through direct injection of lentiviral vectors. The preclinical studies were published in the November issue of Nature Genetics.

No Comments